| Treatment of patients with severe sepsis using ulinastatin and thymosin alpha1: a prospective, randomized, controlled pilot study. | |
| | |
MedLine Citation:
|
PMID: 19493408 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Tradition treatment of sepsis and new therapies, including high dose corticosteroids and non-steroidal anti-inflammatory drugs, have proven unsuccessful in improving survival. This study aimed to evaluate the potential efficacy of immunomodulating therapy using Ulinastatin (UTI) plus Thymosin alpha1 (Talpha1) for improving organ function and reducing mortality in patients with severe sepsis. METHODS: A prospective study was carried out with randomized and controlled clinical analysis of 114 patients conforming to the enrollment standard. All patients had severe sepsis and received standard supportive care and antimicrobial therapy. Fifty-nine patients were also administered UTI plus Talpha1 (defined as Group A), 55 patients were given a placebo (defined as Group B). Clinical parameters were determined by evaluation with the Acute Physiology and Chronic Health Evaluation II (APACHE II), multiple organ failure (MOF) and the Glasgow Coma Scores (GCS) on entry and after therapy on the 3rd, 8th, and 28th day. By flow cytometery and ELISA lymphocyte subsets and cytokines were analyzed. Survival analysis was determined by the Kaplan-Meier method at 28, 60, and 90 days. RESULTS: Based on comparison of the two groups, patients in Group A exhibited a better performance in organ failure scores which was noticeable soon after initiation of treatment. Patients in Group A also demonstrated a better resolution of pre-existing organ failures during the observation period. After initiation of treatment, significant improvements in the CD(4)(+)/CD(8)(+) ratio, a quicker balance between proinflammatory mediators such as tumor necrosis factor alpha, interleukin 6 and anti-inflammatory cytokines including interleukin 4 and interleukin 10 were found. This was followed by cumulative survival increases of 17.3% at 28 days, 28.9% at 60 days, and 31.4% at 90 days in Group A. The reduction in mortality was accompanied by a considerably shorter stay in the ICU and a shorter length of supportive ventilation, antimicrobial and dopamine therapy. CONCLUSION: UTI plus Talpha(1) has a beneficial role in the treatment of severe sepsis. |
| | |
Authors:
|
Hao Chen; Ming-yan He; Yu-min Li |
Related Documents
:
|
7457808 - Anaesthetic complications requiring intensive care. a five year review. 23200598 - Triple positioning of tibial tubercle osteotomy for patellofemoral disorders. 15350708 - Comparison of the effect of closed versus open endotracheal suction systems on the deve... 9349678 - Severe hyponatremia as poor prognostic factor in childhood neurologic diseases. 17124898 - Fulfilling the promise of laser refractive surgery. 23328488 - Comparison of two approaches in microsurgical varicocelectomy in chinese infertile males. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Chinese medical journal Volume: 122 ISSN: 0366-6999 ISO Abbreviation: Chin. Med. J. Publication Date: 2009 Apr |
Date Detail:
|
Created Date: 2009-06-04 Completed Date: 2009-10-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7513795 Medline TA: Chin Med J (Engl) Country: China |
Other Details:
|
Languages: eng Pagination: 883-8 Citation Subset: IM |
Affiliation:
|
The Key Laboratory of Organ Transplantation of Public Health Ministry, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adjuvants, Immunologic
/
therapeutic use* Adult CD4-Positive T-Lymphocytes / immunology CD8-Positive T-Lymphocytes / immunology Female Glycoproteins / therapeutic use* Humans Interleukin-10 / metabolism Interleukin-6 / metabolism Lymphocyte Subsets / immunology Male Middle Aged Sepsis / drug therapy*, metabolism, mortality Survival Analysis Thymosin / analogs & derivatives*, therapeutic use Treatment Outcome Trypsin Inhibitors / therapeutic use* Tumor Necrosis Factor-alpha / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Adjuvants, Immunologic; 0/Glycoproteins; 0/Interleukin-6; 0/Trypsin Inhibitors; 0/Tumor Necrosis Factor-alpha; 0/thymalfasin; 130068-27-8/Interleukin-10; 61512-21-8/Thymosin; 80449-32-7/urinastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Recombinant human bone morphogenetic protein-2 promotes the proliferation of mesenchymal stem cells ...
Next Document: Radiofrequency ablation combined with transarterial chemoembolization for unresectable primary liver...